



Published in final edited form as:

J Pain Symptom Manage. 2014 June ; 47(6): 1100–1115. doi:10.1016/j.jpainsymman.2013.07.014.

Supportive Cryotherapy: A Review from Head to Toe

Kunal C. Kadakia, MD, Shaina A. Rozell, MD, Anish A. Butala, BS, and Charles L. Loprinzi, MD

Division of Internal Medicine (K.C.K., S.A.R.), Mayo Clinic, Houston, Texas; Feinberg School of Medicine (A.A.B.), Northwestern University, Chicago, Illinois; and Division of Medical Oncology (C.I.L.), Mayo Clinic, Rochester, Minnesota, USA

Abstract

Context—Conventional chemotherapy leads to multiple adverse mucocutaneous complications including oral mucositis, alopecia, ocular toxicity, and onycholysis. Limited pharmacologic interventions are available for preventing these clinical problems.

Objectives—This study aimed to critically review the role of cryotherapy (regional hypothermia) for alleviating these adverse symptoms.

Methods—A narrative review was performed, with an emphasis on randomized controlled trials. A comprehensive search using PubMed, Ovid, Embase, and MEDLINE® was completed. References of all cited articles also were reviewed. Data from the review were comprised of articles published between 1970 to May 2013.

Results—Available evidence suggests that regional hypothermia decreases the burden of chemotherapy-related oral mucositis, alopecia, ocular toxicity, and onycholysis. The major limitations of studies include the absence of blinded control groups and variable clinical endpoints.

Conclusion—Regional hypothermia decreases the burden of these four chemotherapy-induced complications and is well tolerated. More research is needed to determine what subgroups of cancer patients are most likely to respond to different types of regional hypothermia, the ideal duration of cooling needed, and to further improve the ease of use of the cooling devices.

Keywords

Cryotherapy; regional hypothermia; mucositis; alopecia; onycholysis

© 2013 U.S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.

Address correspondence to: Charles L. Loprinzi, MD, Division of Medical Oncology, Mayo Clinic, 200 1st Street S.W., Rochester, MN, 55905, USA, cloprinzi@mayo.edu.

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

Disclosures

The authors declare no conflicts of interest.

Introduction

Conventional chemotherapy leads to adverse mucocutaneous complications such as oral mucositis, alopecia, onycholysis, and 5-fluorouracil (5FU)-related ocular toxicity. Despite extensive research, limited pharmacologic interventions are available for preventing these clinical problems. Cryotherapy utilizes the basic principle that cold-induced vasoconstriction can limit the local effects of certain cytotoxic therapies. This review critically appraises the role of cryotherapy in supportive oncology, focusing on the prevention of these four chemotherapy-induced complications.

Oral Mucositis

Oral mucositis (OM) causes oropharyngeal pain and can prevent adequate nutritional intake. Beyond causing significant pain and suffering,¹ it is associated with increased hospitalizations, the need for total parenteral nutrition, and septicemia.^{2,3} As such, this complication leads to significant resource utilization and is a major economic burden.⁴

Pathogenesis of Oral Mucositis

The pathogenesis of chemotherapy-induced mucositis is complex and yet to be fully understood. Although previously believed to be a nonspecific effect of chemotherapy on rapidly dividing cells of the mucosal tract, the pathobiology of mucositis has more recently been described as a sequence of five biological stages. These include initiation, upregulation and message generation (primary damage response), signaling and amplification, ulceration, and healing.⁵ Despite a better understanding of the pathogenesis of mucositis, multiple pharmacologic agents, posited to act at different stages of this sequence, have failed to show consistent benefits in randomized controlled trials (RCT).⁶⁻⁹ For example, glutamine, an amino acid necessary for cell mitosis, could theoretically decrease OM; however, its use has been poorly supported in adequately powered and well-designed RCTs.¹⁰ Other agents, such as palifermin, that interact at multiple stages in this sequence have proven to be beneficial in well-designed RCTs but are only a U.S. Food and Drug Administration-approved preventative agent in certain patients undergoing autologous hematopoietic stem cell transplantation (HSCT).¹¹

Cryotherapy and Oral Mucositis

The mechanism of oral cryotherapy, placing ice chips in the mouth during chemotherapy infusion for the prevention of OM is, at least hypothetically, understood. When developed, it was assumed that such a maneuver would decrease the temperature of the oral cavity. A recent study of 12 healthy patients confirmed that crushed ice in the oral cavity leads to a mean difference of $\approx 13^{\circ}$ C in the oral cavity tissues.¹² Hypothermia leads to vasoconstriction and the resultant reduction in blood flow is posited to decrease the local effects of concentrated levels of cytotoxic drugs in the cooled area.

Since 1991, over 20 controlled and uncontrolled trials have assessed the efficacy of oral cryotherapy for the prevention of OM (Tables 1 and 2). Almost all trials studied its effectiveness in patients receiving chemotherapeutics with a short serum half-life, such as bolus 5FU and high-dose melphalan. Mahood et al. were the first to observe that

cryotherapy reduced 5FU-induced OM, by ~50%.¹³ In a confirmatory analysis, 84 patients were randomized to either oral cryotherapy or control and a similar reduction in the mean OM toxicity score was observed.¹⁴ Following the results of these pivotal trials, French and Italian researchers found cryotherapy effective in reducing OM in patients undergoing conditioning regimens containing high-dose melphalan.^{15, 16} However, one of the limitations of these early trials was that they did not assess for pre-treatment oral health. Although the optimal regimen of oral care remains to be determined,¹⁷ maintaining adequate oral hygiene prior to and following chemotherapy and radiation appears to reduce the incidence and severity of OM.^{18, 19}

Beyond reducing the incidence of OM in patients receiving such chemotherapy, further trials have demonstrated the effectiveness of cryotherapy in reducing the duration of OM, its effect with different chemotherapeutic regimens, utility with other prophylactic agents, and the optimal duration of cryotherapy itself.

In 2005, 60 patients with solid tumors receiving varying combinations of etoposide, cisplatin, vinblastine, and mitomycin were randomized to cryotherapy or standard treatment.²⁰ The patients allocated to cryotherapy had less mucositis as well as a shorter mean duration of OM (7 vs. 12 days). The shortened course of OM also was observed in other trials, most averaging a reduction of approximately four days.^{13, 21}

Edatrexate, an analogue of methotrexate with a short serum half-life, has been used with marginal success in regimens for both solid and liquid tumors, with the major dose-limiting side effects being OM and myelosuppression. In a phase I trial of 46 patients receiving edatrexate plus carboplatin in advanced solid tumors, only 15% had Grade 3/4 OM with the use of cryotherapy,²² less OM than was seen in trials not using cryotherapy.^{23, 24} Two other trials found mixed results with cryotherapy in patients receiving edatrexate.^{25, 26}

Although allopurinol mouthwashes alone do not consistently appear to prevent OM,^{10, 27, 28} its role combined with cryotherapy (i.e., allopurinol ice balls) was shown to be promising in a Japanese trial.²⁹ In contrast to all previous trials, the patients were administered allopurinol ice balls during the infusion as well as at two, four, and six hours post-infusion. To address whether a longer duration of cryotherapy in patients receiving 5FU is needed, 178 patients were randomized to either 30 or 60 minutes of cooling and no difference was observed between groups, supporting that 30 minutes was adequate.³⁰

Five more recent trials also have reported a clear benefit of oral cryotherapy over standard care alone in patients receiving 5FU. The earliest of these found a clear benefit of either oral cryotherapy regimen over control; however, no patient preference of flavored vs. plain ice cryotherapy was observed.³¹ Patients receiving flavored ice were more likely to complain of nausea, oral sensitivity, and headaches. Papadeas et al. confirmed the persistent benefit of oral cryotherapy over three cycles of chemotherapy.³² In the largest RCT to date, oral cryotherapy and chlorhexidine significantly decreased the incidence of Grade 3 OM over normal saline.²¹ Compliance rates were the highest for the cryotherapy arm; however, this arm was associated with significantly more headaches.

In patients undergoing melphalan-containing conditioning regimens, initial reports suggested the benefit of oral cryotherapy in nonrandomized studies as described above.^{15, 16} Since then, three nonrandomized and three randomized studies have shown significant benefit for OM with the use of oral cryotherapy in this patient population (Table 2).^{15, 16, 33-38} To address the optimal duration of cryotherapy in patients receiving melphalan, a study found that a total duration of cryotherapy for 60 minutes compared with 120 minutes improved tolerability without decreasing efficacy.³⁶ Other studies in patients undergoing HSCT have shown that oral cryotherapy also reduces opioid use³⁷ and decreases the need for parenteral nutrition.³⁸

Despite the above positive data, a large randomized multicenter study found no significant difference between cryotherapy compared with standard therapy in patients receiving low-dose methotrexate following allogeneic HSCT (47% vs. 53%).³⁹ Although the researchers found that peak methotrexate plasma levels occur within 30 minutes of infusion, the elimination half-life and methotrexate by-products likely decreased the efficacy compared with studies involving melphalan and 5FU. Given the large number of positive studies and virtual lack of negative studies (except for the study noted above), it is reasonable to consider a potential publication bias. However, it is unlikely that there is more of a publication bias in this setting versus other settings with multiple positive studies.

Adverse Effects of Cryotherapy for Oral Mucositis

Most patients tolerate oral cryotherapy without serious issues. The most common adverse effects reported include headaches, nausea, and chills. Some patients note a subsequent aversion to ice, as it can bring back memories of other chemotherapy-induced toxicities such as dysgeusia. A recent report found no serious adverse effects such as an increased relapse rate in hematological cancers over a five-year period.⁴⁰

Chemotherapy-Induced Alopecia

Chemotherapy-induced alopecia (CIA) is a common and distressing adverse effect of cancer treatment that can negatively impact quality of life.⁴¹⁻⁴³ The incidence and severity of alopecia is dependent on the route, dose, and schedule of the cytotoxic drugs utilized.⁴⁴ Hair loss generally occurs two to four weeks after the initiation of chemotherapy and regrowth occurs three to six months following cessation of therapy, although irreversible hair loss does rarely occur.^{45, 46} Therapy to prevent the occurrence of alopecia is desired as it is a feared complication of cancer treatment, and nearly 10% of women would consider refusing chemotherapy, because of it.⁴⁷⁻⁵⁰

Pathogenesis of Chemotherapy-Induced Alopecia

The pathophysiology of CIA is complex and not fully understood. Much of the understanding has been gleaned from studies involving newborn rats, the C57BL/6 mouse model, and more recently an adult rat model.⁵¹⁻⁵³ Two broad mechanisms are felt to be responsible for hair loss: thinning of the hair shaft leading to breakage and inhibition of dividing hair matrix cells resulting in hair separation from the bulb (anagen effluvium). Both processes are related, in part, to the capacity of cytotoxic therapy to impair mitotic activity

and induce apoptosis. The molecular mechanisms of chemotherapy-induced apoptosis continue to be elucidated and activation of p53 plays a critical role in the development of CIA.⁵⁴

Delivery of scalp hypothermia (i.e., cryotherapy) can occur in the form of an ice turban, gel cap, cool cap, or a thermocirculator. It involves physically decreasing the amount of cytotoxic drug that is delivered to the scalp. It is theorized that scalp hypothermia triggers vasoconstriction of local blood vessels, thereby limiting temperature dependent absorption of cytotoxic therapy and reducing local tissue metabolism by the hair follicle.^{55, 56}

Cryotherapy and Chemotherapy-Induced Alopecia

In the 1970s, scalp hypothermia was initially reported to improve alopecia in patients receiving doxorubicin.⁵⁷⁻⁵⁹ Since then, there have been more than 50 nonrandomized and seven randomized studies evaluating its efficacy in diverse patient populations; patients with breast cancer remain the most studied group. A comprehensive review, published in 2005, concluded that the majority of findings were positive, with an average success rate prior to and after 1995 of 56% and 73%, respectively (most often based on the World Health Organization [WHO] alopecia grading criteria and less frequently on the need for a wig or a head cover).⁶⁰ Six of the seven randomized trials ($N=233$) published to date were positive and, of these, five occurred in the 1970s and 1980s,^{58, 61-64} whereas only two were more recent.^{65, 66} Although the chemotherapy regimens used in these earlier studies differed from more recent studies, other methodological variables including scalp-cooling technique, post-infusion cooling times, duration of chemotherapy infusion, and eligibility criteria make comparisons between studies difficult.

Since the review published in 2005,⁶⁰ there have been nine studies evaluating the efficacy of scalp hypothermia (one systematic review and eight nonrandomized studies) (Table 3). The systematic review only included three of the older randomized controlled studies because of methodological issues and tentatively recommended the use of scalp hypothermia.⁶⁷ In 2009, a study involving breast cancer patients found that scalp hypothermia significantly reduced the need for a wig or a head cover compared with control.⁶⁸ Scalp hypothermia was felt to be burdensome in a minority of the group (33%), with a common concern being that scalp cooling will fail to prevent hair loss. In a separate analysis by the authors, successfully cooled patients had an improved feeling of well-being; however, patients who were unsuccessfully cooled reported the highest degree of distress.⁴³

In another study of 64 patients, primarily with breast cancer, 83% of patients using a scalp-cooling gel-cap reported Grade 0/1 alopecia and only 17% had Grade 3 alopecia.⁶⁹ The majority of patients did not report any side effects (57%), and tolerable side effects were reported by 30%. Only four patients discontinued the use of the scalp-cooling gel-cap because the process was too unpleasant or cold.

In 2011, Karger et al. completed a study of 63 patients with various cancers and compared the scalp-cooling group with a control group; they found greater benefit earlier in the course of therapy, suggesting a component of cumulative toxicity from chemotherapy leading to

less benefit from scalp cooling during subsequent cycles.⁷⁰ The authors did not mention any significant adverse effects of therapy.

The largest cohort ever studied, comprising 1411 patients from the Dutch Scalp Cooling Registry, found that the overall use of head covering (wig or other) was 50% within the entire cohort but varied from 5-10% with low-dose docetaxel or paclitaxel to more than 90% of patients receiving combination regimens.⁷¹ Higher chemotherapy doses, shorter infusion times, non-Western European hair, female gender, and older age were associated with a higher use of head covers. Median pre- and post-infusion cooling times were significantly longer than the reported pre- and post-infusion times in the more recent studies. A subsequent study by the same authors found that a shorter post-infusion cooling time was as effective as a longer post-infusion cooling time (45 vs. 90 minutes).⁷²

A recent prospective cohort study, available only in abstract form, found that scalp hypothermia significantly reduced alopecia compared with a control group.⁷³ Compared with hairstylist assessments, patient-reported assessments suggested a greater degree of benefit, highlighting the significance of patient expectations in this study. Adverse effects and quality-of-life measurements are yet to be published.

The most recent study comparing the Paxman cooling system with another cold cap (manufacturer not specified) found a significant decrease in alopecia in patients receiving either form of scalp hypothermia.⁷⁴ Importantly, a shorter post-infusion cooling time (45 vs. 90 minutes) was again found to be effective.

Adverse Effects of Scalp Hypothermia

Most patients tolerate scalp hypothermia well; however, a few may find it too cumbersome, lengthy, or intolerable. Although uncommon, adverse effects include headaches,^{68,75} extreme coldness,^{69, 76} or a heavy sensation.⁶⁹ Rare side effects include nausea, dizziness, or anxiety.^{76, 77}

Risk of Scalp Metastases and Influence of Drug Metabolism

Two case reports of scalp metastases associated with scalp hypothermia in patients with hematological malignancies have been reported.^{78,79} Although similar concerns have been raised in patients with solid tumors, more recent evidence suggests that this risk is minimal. The incidence of scalp metastases was 0.45% in one large retrospective study (two of 442 patients).⁸⁰ The incidence of scalp metastases in another retrospective cohort was similar in patients undergoing scalp hypothermia or not (1.1% vs. 1.2%).⁸¹ The large Dutch registry of 1411 patients has yet to observe a scalp metastasis within its entire cohort.⁷¹ Given the lack of supporting data to suggest safety in patients with hematological malignancies and the aforementioned case reports, scalp hypothermia is not recommended for this population.

Initial reports of severe alopecia in patients with liver insufficiency treated with doxorubicin despite scalp hypothermia suggest the influence of drug metabolism as a predictor of scalp hypothermia failure.^{82, 83} More recent studies also suggest that liver insufficiency could lead to higher rates of alopecia despite scalp hypothermia.⁶⁰

Chemotherapy-Induced Onycholysis

A variety of changes to the nail can occur because of chemotherapy including onycholysis (detachment or loosening of the nail from the nail bed). Beyond aesthetic disfigurement, onycholysis can be painful, can increase the chance of superimposed infection and can delay chemotherapy administration.⁸⁴ It is most commonly associated with taxanes including docetaxel and paclitaxel but its occurrence because of other chemotherapeutic agents can occur. The incidence of taxane-induced onycholysis is variable (5-30%) depending on the specific taxane used (the risk with docetaxel is greater than that with paclitaxel) and the dosing schedule.^{85, 86}

Pathogenesis of Chemotherapy-Induced Onycholysis

Although the etiology of chemotherapy-induced onycholysis remains to be elucidated, direct cytotoxic, vascular, and neurogenic mechanisms have been postulated. A thin nail bed epithelium is responsible for supporting the adhesion of the nail plate to the nail bed. Chemotherapy-related cytotoxic injury to this epithelium could contribute to the development of onycholysis.^{84, 87} A neurogenic mechanism was first proposed based on the sparing of toxicity in the paretic hand of a patient who had docetaxel-induced onycholysis in the other three extremities.⁸⁸ The authors hypothesized two particular neurogenic mechanisms: the first is related to persistent neurogenic inflammation from taxane-induced *stimulation* of cutaneous nociceptive C-fibers and the second is related to taxane-induced release of pro-inflammatory mediators that promote *maintenance* of nociceptive primary afferent stimulus (peripheral sensitization).

Cryotherapy and Chemotherapy-Induced Onycholysis

Similar to scalp hypothermia and oral cryotherapy, the suspected mechanism of regional hypothermia in the prevention of onycholysis is likely related to local vasoconstriction leading to reduced levels of cytotoxic drug to the nail bed and matrix. Based on the efficacy of cryotherapy for alopecia and mucositis, multiple studies evaluating regional hypothermia for prevention of nail toxicity have been completed (Table 4). Scotté et al. reported a case-control trial of 45 patients, using an Elasto-Gel frozen glove with the patient's left hand used as a control, for the prevention of docetaxel-induced onycholysis and skin toxicity.⁸⁹ Nail toxicity was significantly less in the frozen glove protected hand. Most patients were satisfied with treatment. However, 11% withdrew because of cold intolerance. The same authors conducted a similarly designed matched case-control trial using a frozen sock and found significantly less docetaxel-induced onycholysis and skin toxicity in the protected foot.⁹⁰ Only one patient was dissatisfied with the treatment because of cold intolerance. Two further studies, each reported in abstract form, found similar benefits with frozen glove therapy with no serious adverse effects reported except discomfort.^{91, 92}

To evaluate the ideal duration and degree of cooling necessary to prevent nail toxicity and maintain comfort, Ishiguro et al. compared a standard frozen glove worn for 90 minutes to a glove worn for 60 minutes.⁹³ At five months, patients in the 60-minute group had a similar degree of nail toxicity with less discomfort, suggesting that the shorter duration intervention

worked as well as the more intense treatment. Docetaxel exposure over the study period did not correlate with nail toxicity.

Despite the aforementioned positive studies, a recent study of 55 patients receiving either taxane were treated with frozen gloves and socks on all extremities and were compared with a similar cohort; no statistical difference was observed in nail toxicity between groups.⁹⁴ Possible explanations for the lack of effect observed include the variety of chemotherapy regimens used in both groups and, more importantly, the differences among individuals, as opposed to each individual being their own control (i.e., using one side to compare to the other).

Adverse Effects of Extremity Hypothermia

The major adverse effect observed in clinical studies includes discomfort related to the degree of cooling and the duration of use. A minority of studied patients (\approx 2-10%) stopped the intervention because of discomfort. One case report described frostbite occurring in the fingers of a man who used frozen gloves (cooled to -25 to -30°C and worn for 90 minutes) during one cycle of docetaxel therapy, which improved with supportive care and subsequent avoidance of frozen gloves.⁹⁵

5FU-Related Ocular Toxicity

Many types of ocular toxicity related to anticancer treatments have been described in patients receiving cytotoxic⁹⁶ as well as targeted therapy.⁹⁷ Ocular toxicities related to 5FU can be divided into complications of the ocular surface, ocular adnexa, or the lacrimal system. Based on 210 patients, receiving a variety of chemotherapy agents, unpleasant ocular symptoms were reported by \approx 40% of patients receiving 5FU-containing regimens compared with \approx 20% of patients receiving non-5FU-containing regimens, suggesting a strong association of 5FU exposure with ocular toxicity.⁹⁸ The most frequent adverse symptoms included tearing (27%), blurred vision (11%), ocular irritation with pain (6%), and eyelid dermatitis (6%).⁹⁹ 5-FU-related ocular symptoms generally occur within 11 to 17 days of the infusion and resolve after 10-15 days.⁹⁸ Although not life-threatening, these adverse symptoms can cause suffering and delay chemotherapy administration.

Pathogenesis of 5FU-Related Ocular Toxicity

Damage of the conjunctiva, cornea and the eyelid margin within days to weeks of 5FU administration is likely related to the cytotoxic effect on the rapidly proliferating cellular elements of these ocular surfaces. Two proposed mechanisms for the etiology of tearing, the most common adverse effect, have been suggested. One theory postulates a reflex phenomenon as a result of direct cytotoxic irritation of the ocular surface.¹⁰⁰ As drug levels are detectable in tears of patients receiving 5FU, the second theory proposes irritation of the lacrimal gland leading to hypersecretion.¹⁰¹ Concentrations of 5FU in tears, in a small series of 12 patients, were not found to be associated with adverse symptoms,⁹⁸ but were associated with symptoms in another series of 13 patients.¹⁰² More prolonged administration of 5FU (more than three months) can lead to chronic inflammation of the lacrimal system

and has been associated with punctal-canalicular stenosis that can rarely result in permanent excessive lacrimation requiring surgical correction.¹⁰³

Cryotherapy and 5FU-Related Ocular Toxicity

In 1990, an initial report of eight patients receiving cyclophosphamide, methotrexate, and 5FU (CMF), who had ocular toxicity on a previous cycle of CMF, were treated with ice packs over their eyes for a total of 30 minutes prior to and during the 5FU infusion. The majority had a decrease in adverse ocular symptoms during the next month.⁹⁸ The postulated mechanism is likely similar to that of cryotherapy for other indications, in that regional hypothermia induces constriction of the blood vessels around the eye resulting in reduced cytotoxic effect during peak 5FU serum concentration. Based on these pilot data, a randomized crossover trial was conducted in 62 patients who had previously complained of ocular toxicity and were undergoing additional 5FU therapy.¹⁰⁴ Ice packs were provided five minutes prior to bolus 5FU infusion and continued for a total of 30 minutes. Mean total ocular toxicity was reduced in patients receiving ocular ice therapy (20 vs. 29 units, $P=0.056$). Although generally well tolerated, unpleasant side effects, such as “feeling cold,” “sore sinuses,” and headaches occurred in 22% of patients.

Conclusions for Supportive Cryotherapy

The majority of studies addressing the use of supportive cryotherapy have shown benefit in preventing oral mucositis, alopecia, onycholysis, and 5FU-related ocular toxicity. The major limitations of these studies are the variability of study design and the lack of blinding. The latter issue is not technically feasible given the nature of the intervention. Although the ideal technique for providing supportive cryotherapy for each of these issues remains to be elucidated, a few conclusions can be made.

Oral cryotherapy has demonstrated a reduction in incidence, severity, and duration of OM (by approximately 50% compared with standard care) in multiple controlled studies involving patients with a variety of cancers receiving bolus 5FU and conditioning regimens containing melphalan. Its role with other cytotoxic regimens such as edatrexate is promising. However, it would not be expected to be effective with chemotherapeutics with longer half-lives. In patients receiving bolus 5FU, crushed ice should be given five minutes prior to infusion and be continued for at least 30 minutes. Based on available evidence, the duration of cryotherapy in patients receiving melphalan-containing conditioning regimens can be increased to 60 minutes, if tolerated. A recent systematic review¹⁰⁵ and the most recent Multinational Association of Supportive Care in Cancer oral mucositis guidelines¹⁰⁶ support these recommendations. Areas of potential further research include the role of oral cryotherapy with other chemotherapy regimens, its efficacy in pediatric populations, and comparisons with promising pharmacological interventions used for OM.

Scalp hypothermia reduces the burden of chemotherapy-induced alopecia. Its role has largely been studied in patients with breast cancer; however, significant distress related to alopecia in male cancer patients warrants further investigation in this population.^{107, 108} Although the ideal technique for cooling has yet to be elucidated, recent reports have yielded promising data regarding the optimal degree of cooling necessary⁵⁵ and the duration of post-

infusion cooling.^{72, 74} Further studies comparing different cooling techniques are needed. Finding more user-friendly means of providing effective scalp hypothermia would be helpful. As research progresses, formal guidelines regarding the role of cryotherapy for alopecia will be warranted.

Although nail toxicity is not life threatening, onycholysis can be disfiguring, painful, and delay chemotherapy administration. The majority of clinical data supports that regional hypothermia of the hands and feet decreases the incidence of onycholysis, with minimal discomfort. It appears to be most consistently effective in patients receiving one-hour infusions of docetaxel. A single trial reported similar benefit with a more tolerable regimen (glove cooled to -10 to -20°C and worn for 60 minutes compared with -25 to -30°C for 90 minutes).⁹³

Cryotherapy also appears to be an effective and tolerable intervention for short-term ocular toxicity related to bolus 5FU infusions. Many current chemotherapy regimens, however, utilize continuous infusions of 5FU, and cryotherapy would likely not provide benefit for these patients. Although largely of historical significance, ocular ice therapy further supports the role of regional hypothermia for certain chemotherapy-induced complications.

Acknowledgments

This work was supported by National Institutes of Health Grant CA 124477 (Principal Investigator: Charles/ Loprinzi, MD).

References

1. Kim JW, Cha Y, Kim SJ, et al. Association of oral mucositis with quality of life and symptom clusters in patients with solid tumors receiving chemotherapy. *Support Care Cancer*. 2012; 20:395–403. [PubMed: 21390568]
2. Ruescher TJ, Sodeifi A, Scrivani SJ, Kaban LB, Sonis ST. The impact of mucositis on alpha-hemolytic streptococcal infection in patients undergoing autologous bone marrow transplantation for hematologic malignancies. *Cancer*. 1998; 82:2275–2281. [PubMed: 9610710]
3. Vera-Llonch M, Oster G, Ford CM, Lu J, Sonis S. Oral mucositis and outcomes of allogeneic hematopoietic stem-cell transplantation in patients with hematologic malignancies. *Support Care Cancer*. 2007; 15:491–496. [PubMed: 17139495]
4. Elting LS, Cooksley C, Chambers M, et al. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. *Cancer*. 2003; 98:1531–1539. [PubMed: 14508842]
5. Sonis ST. Pathobiology of oral mucositis: novel insights and opportunities. *J Support Oncol*. 2007; 5(9 Suppl 4):3–11. [PubMed: 18046993]
6. van der Lelie H, Thomas BL, van Oers RH, et al. Effect of locally applied GM-CSF on oral mucositis after stem cell transplantation: a prospective placebo-controlled double-blind study. *Ann Hematol*. 2001; 80:150–154. [PubMed: 11320899]
7. de Koning BA, Philipsen-Geerling B, Hoijer M, et al. Protection against chemotherapy induced mucositis by TGF-beta(2) in childhood cancer patients: results from a randomized cross-over study. *Pediatr Blood Cancer*. 2007; 48:532–539. [PubMed: 16767731]
8. Duenas-Gonzalez A, Sobrevilla-Calvo P, Frias-Mendivil M, et al. Misoprostol prophylaxis for high-dose chemotherapy-induced mucositis: a randomized double-blind study. *Bone Marrow Transplant*. 1996; 17:809–812. [PubMed: 8733702]
9. Loprinzi CL, Ghosh C, Camoriano J, et al. Phase III controlled evaluation of sucralfate to alleviate stomatitis in patients receiving fluorouracil-based chemotherapy. *J Clin Oncol*. 1997; 15:1235–1238. [PubMed: 9060567]

10. Worthington HV, Clarkson JE, Bryan G, et al. Interventions for preventing oral mucositis for patients with cancer receiving treatment. *Cochrane Database Syst Rev.* 2011(4):CD000978. [PubMed: 21491378]
11. Spielberger R, Stiff P, Bensinger W, et al. Palifermin for oral mucositis after intensive therapy for hematologic cancers. *N Engl J Med.* 2004; 351:2590–2598. [PubMed: 15602019]
12. Svanberg A, Ohn K, Brostrom H, Birgegard G. The effect of cryotherapy on oral mucosa: a study in healthy volunteers. *Med Oncol.* 2012; 29:3587–3591. [PubMed: 22476810]
13. Mahood DJ, Dose AM, Loprinzi CL, et al. Inhibition of fluorouracil-induced stomatitis by oral cryotherapy. *J Clin Oncol.* 1991; 9:449–452. [PubMed: 1999715]
14. Cascinu S, Fedeli A, Fedeli SL, Catalano G. Oral cooling (cryotherapy), an effective treatment for the prevention of 5-fluorouracil-induced stomatitis. *Eur J Cancer B Oral Oncol.* 1994; 30B:234–236. [PubMed: 7950836]
15. Dumontet C, Sonnet A, Bastion Y, et al. Prevention of high dose L-PAM-induced mucositis by cryotherapy. *Bone Marrow Transplant.* 1994; 14:492–494. [PubMed: 7994283]
16. Meloni G, Capria S, Proia A, Trisolini SM, Mandelli F. Ice pops to prevent melphalan-induced stomatitis. *Lancet.* 1996; 347:1691–1692. [PubMed: 8642978]
17. Kenny SA. Effect of two oral care protocols on the incidence of stomatitis in hematology patients. *Cancer Nurs.* 1990; 13:345–353. [PubMed: 2276107]
18. Hogan R. Implementation of an oral care protocol and its effects on oral mucositis. *J Pediatr Oncol Nurs.* 2009; 26:125–135. [PubMed: 19380885]
19. McGuire DB, Correa ME, Johnson J, Wienandts P. The role of basic oral care and good clinical practice principles in the management of oral mucositis. *Support Care Cancer.* 2006; 14:541–547. [PubMed: 16775649]
20. Karagozoglu S, Filiz Ulusoy M. Chemotherapy: the effect of oral cryotherapy on the development of mucositis. *J Clin Nurs.* 2005; 14:754–765. [PubMed: 15946284]
21. Sorensen JB, Skovsgaard T, Bork E, Damstrup L, Ingeberg S. Double-blind, placebo-controlled, randomized study of chlorhexidine prophylaxis for 5-fluorouracil-based chemotherapy-induced oral mucositis with nonblinded randomized comparison to oral cooling (cryotherapy) in gastrointestinal malignancies. *Cancer.* 2008; 112:1600–1606. [PubMed: 18300265]
22. Edelman MJ, Gandara DR, Perez EA, et al. Phase I trial of edatrexate plus carboplatin in advanced solid tumors: amelioration of dose-limiting mucositis by ice chip cryotherapy. *Invest New Drugs.* 1998; 16:69–75. [PubMed: 9740546]
23. Meyers FJ, Lew D, Lara PN Jr. et al. Phase II trial of edatrexate in relapsed or refractory germ cell tumors: a Southwest Oncology Group study (SWOG 9124). *Invest New Drugs.* 1998; 16:347–351. [PubMed: 10426670]
24. Broun ER, Iseminger KA, Rose PG, et al. A phase II trial of edatrexate in previously treated squamous cell cervical cancer: a Gynecologic Oncology Group study. *Am J Clin Oncol.* 1997; 20:78–80. [PubMed: 9020294]
25. Dreicer R, Probert KJ, Kuzel T, et al. A phase II trial of edatrexate in patients with advanced renal cell carcinoma. An Eastern Cooperative Oncology Group study. *Am J Clin Oncol.* 1997; 20:251–253. [PubMed: 9167747]
26. Gandara DR, Edelman MJ, Crowley JJ, Lau DH, Livingston RB. Phase II trial of edatrexate plus carboplatin in metastatic non-small-cell lung cancer: a Southwest Oncology Group study. *Cancer Chemother Pharmacol.* 1997; 41:75–78. [PubMed: 9443617]
27. Loprinzi CL, Cianflone SG, Dose AM, et al. A controlled evaluation of an allopurinol mouthwash as prophylaxis against 5-fluorouracil-induced stomatitis. *Cancer.* 1990; 65:1879–1882. [PubMed: 2180557]
28. Panahi Y, Ala S, Saeedi M, et al. Allopurinol mouth rinse for prophylaxis of fluorouracil-induced mucositis. *Eur J Cancer Care.* 2010; 19:308–312.
29. Yokomizo H, Yoshimatsu K, Hashimoto M, et al. Prophylactic efficacy of allopurinol ice ball for leucovorin/5-fluorouracil therapy-induced stomatitis. *Anticancer Res.* 2004; 24:1131–1134. [PubMed: 15154636]

30. Rocke LK, Loprinzi CL, Lee JK, et al. A randomized clinical trial of two different durations of oral cryotherapy for prevention of 5-fluorouracil-related stomatitis. *Cancer*. 1993; 72:2234–2238. [PubMed: 8374882]
31. Nikoletti S, Hyde S, Shaw T, Myers H, Kristjanson LJ. Comparison of plain ice and flavoured ice for preventing oral mucositis associated with the use of 5 fluorouracil. *J Clin Nurs*. 2005; 14:750–753. [PubMed: 15946283]
32. Papadeas E, Naxakis S, Riga M, Kalofonos C. Prevention of 5-fluorouracil-related stomatitis by oral cryotherapy: a randomized controlled study. *Eur J Oncol Nurs*. 2007; 11:60–65. [PubMed: 16829196]
33. Aisa Y, Mori T, Kudo M, et al. Oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. *Support Care Cancer*. 2005; 13:266–269. [PubMed: 15668755]
34. Bhatt V, Vendrell N, Nau K, Crumb D, Roy V. Implementation of a standardized protocol for prevention and management of oral mucositis in patients undergoing hematopoietic cell transplantation. *J Oncol Pharm Pract*. 2010; 16:195–204. [PubMed: 19910393]
35. Lilleby K, Garcia P, Gooley T, et al. A prospective, randomized study of cryotherapy during administration of high-dose melphalan to decrease the severity and duration of oral mucositis in patients with multiple myeloma undergoing autologous peripheral blood stem cell transplantation. *Bone Marrow Transplant*. 2006; 37:1031–1035. [PubMed: 16633359]
36. Mori T, Yamazaki R, Aisa Y, et al. Brief oral cryotherapy for the prevention of high-dose melphalan-induced stomatitis in allogeneic hematopoietic stem cell transplant recipients. *Support Care Cancer*. 2006; 14:392–395. [PubMed: 16633843]
37. Svanberg A, Birgegard G, Ohrn K. Oral cryotherapy reduces mucositis and opioid use after myeloablative therapy--a randomized controlled trial. *Support Care Cancer*. 2007; 15:1155–1161. [PubMed: 17393189]
38. Svanberg A, Ohrn K, Birgegard G. Oral cryotherapy reduces mucositis and improves nutrition - a randomised controlled trial. *J Clin Nurs*. 2010; 19:2146–2151. [PubMed: 20659194]
39. Gori E, Arpinati M, Bonifazi F, et al. Cryotherapy in the prevention of oral mucositis in patients receiving low-dose methotrexate following myeloablative allogeneic stem cell transplantation: a prospective randomized study of the Gruppo Italiano Trapianto di Midollo Osseo nurses group. *Bone Marrow Transplant*. 2007; 39:347–352. [PubMed: 17277790]
40. Svanberg A, Ohrn K, Birgegard G. Five-year follow-up of survival and relapse in patients who received cryotherapy during high-dose chemotherapy for stem cell transplantation shows no safety concerns. *Eur J Cancer Care*. 2012; 21:822–828.
41. Rosman S. Cancer and stigma: experience of patients with chemotherapy-induced alopecia. *Patient Educ Counsel*. 2004; 52:333–339.
42. Mulders M, Vingerhoets A, Breed W. The impact of cancer and chemotherapy: perceptual similarities and differences between cancer patients, nurses and physicians. *Eur J Oncol Nurs*. 2008; 12:97–102. [PubMed: 18242139]
43. van den Hurk CJ, Mols F, Vingerhoets AJ, Breed WP. Impact of alopecia and scalp cooling on the well-being of breast cancer patients. *Psychooncology*. 2010; 19:701–709. [PubMed: 19637250]
44. Trueb RM. Chemotherapy-induced alopecia. *Semin Cutan Med Surg*. 2009; 28:11–14. [PubMed: 19341937]
45. Machado M, Moreb JS, Khan SA. Six cases of permanent alopecia after various conditioning regimens commonly used in hematopoietic stem cell transplantation. *Bone Marrow Transplant*. 2007; 40:979–982. [PubMed: 17846605]
46. Tallon B, Blanchard E, Goldberg LJ. Permanent chemotherapy-induced alopecia: case report and review of the literature. *J Am Acad Dermatol*. 2010; 63:333–336. [PubMed: 20471136]
47. Tierney AJ, Taylor J, Closs SJ. Knowledge, expectations and experiences of patients receiving chemotherapy for breast cancer. *Scand J Caring Sci*. 1992; 6:75–80. [PubMed: 1641535]
48. Lemieux J, Maunsell E, Provencher L. Chemotherapy-induced alopecia and effects on quality of life among women with breast cancer: a literature review. *Psychooncology*. 2008; 17:317–328. [PubMed: 17721909]

49. Coates A, Abraham S, Kaye SB, et al. On the receiving end--patient perception of the side-effects of cancer chemotherapy. *Eur J Cancer Clin Oncol.* 1983; 19:203–208. [PubMed: 6681766]
50. Baxley KO, Erdman LK, Henry EB, Roof BJ. Alopecia: effect on cancer patients' body image. *Cancer Nurs.* 1984; 7:499–503. [PubMed: 6568869]
51. Hussein AM, Jimenez JJ, McCall CA, Yunis AA. Protection from chemotherapy-induced alopecia in a rat model. *Science.* 1990; 249:1564–1566. [PubMed: 2218498]
52. Paus R, Handjiski B, Eichmuller S, Czarnetzki BM. Chemotherapy-induced alopecia in mice. Induction by cyclophosphamide, inhibition by cyclosporine A, and modulation by dexamethasone. *Am J Pathol.* 1994; 144:719–734. [PubMed: 8160773]
53. Wikramanayake TC, Amini S, Simon J, et al. A novel rat model for chemotherapy-induced alopecia. *Clin Exp Dermatol.* 2012; 37:284–289. [PubMed: 22409523]
54. Botchkarev VA. Molecular mechanisms of chemotherapy-induced hair loss. *J Investig Dermatol Symp Proc.* 2003; 8:72–75.
55. Janssen FP, Bouten CV, van Leeuwen GM, van Steenhoven AA. Effects of temperature and doxorubicin exposure on keratinocyte damage in vitro. *In vitro cellular & developmental biology. Animal.* 2008; 44:81–86. [PubMed: 18193326]
56. Gregory RP, Cooke T, Middleton J, Buchanan RB, Williams CJ. Prevention of doxorubicin-induced alopecia by scalp hypothermia: relation to degree of cooling. *BMJ.* 1982; 284:1674. [PubMed: 6805650]
57. Luce J, Raffetto T, Crisp I, Grief G. Prevention of alopecia by scalp cooling in patients receiving adriamycin. *Cancer Chemother Rep.* 1973; 57:108.
58. Edelstyn GA, MacDonald M, MacRae KD. Doxorubicin-induced hair loss and possible modification by scalp cooling. *Lancet.* 1977; 2:253–254. [PubMed: 69866]
59. Dean JC, Salmon SE, Griffith KS. Prevention of doxorubicin-induced hair loss with scalp hypothermia. *N Engl J Med.* 1979; 301:1427–1429. [PubMed: 514322]
60. Grevelman EG, Breed WP. Prevention of chemotherapy-induced hair loss by scalp cooling. *Ann Oncol.* 2005; 16:352–358. [PubMed: 15642703]
61. Giaccone G, Di Giulio F, Morandini MP, Calciati A. Scalp hypothermia in the prevention of doxorubicin-induced hair loss. *Cancer Nurs.* 1988; 11:170–173. [PubMed: 3401852]
62. Kennedy M, Packard R, Grant M, et al. The effects of using Chemocap on occurrence of chemotherapy-induced alopecia. *Oncol Nurs Forum.* 1983; 10:19–24. [PubMed: 6553308]
63. Parker R. The effectiveness of scalp hypothermia in preventing cyclophosphamide-induced alopecia. *Oncol Nurs Forum.* 1987; 14:49–53. [PubMed: 3697290]
64. Satterwhite B, Zimm S. The use of scalp hypothermia in the prevention of doxorubicin-induced hair loss. *Cancer.* 1984; 54:34–37. [PubMed: 6372986]
65. Macduff C, Mackenzie T, Hutcheon A, Melville L, Archibald H. The effectiveness of scalp cooling in preventing alopecia for patients receiving epirubicin and docetaxel. *Eur J Cancer Care.* 2003; 12:154–161.
66. Ron IG, Kalmus Y, Kalmus Z, Inbar M, Chaitchik S. Scalp cooling in the prevention of alopecia in patients receiving depilating chemotherapy. *Support Care Cancer.* 1997; 5:136–138. [PubMed: 9069614]
67. Lotfi-Jam K, Carey M, Jefford M, et al. Nonpharmacologic strategies for managing common chemotherapy adverse effects: a systematic review. *J Clin Oncol.* 2008; 26:5618–5629. [PubMed: 18981466]
68. Mols F, van den Hurk CJ, Vingerhoets AJ, Breed WP. Scalp cooling to prevent chemotherapy-induced hair loss: practical and clinical considerations. *Support Care Cancer.* 2009; 17:181–189. [PubMed: 18560904]
69. Auvinen PK, Mahonen UA, Soininen KM, et al. The effectiveness of a scalp cooling cap in preventing chemotherapy-induced alopecia. *Tumori.* 2010; 96:271–275. [PubMed: 20572585]
70. Kargar M, Sarvestani RS, Khojasteh HN, Heidari MT. Efficacy of penguin cap as scalp cooling system for prevention of alopecia in patients undergoing chemotherapy. *J Adv Nurs.* 2011; 67:2473–2477. [PubMed: 21635283]

71. van den Hurk CJ, Peerbooms M, van de Poll-Franse LV, et al. Scalp cooling for hair preservation and associated characteristics in 1411 chemotherapy patients - results of the Dutch Scalp Cooling Registry. *Acta Oncol.* 2012; 51:497–504. [PubMed: 22304489]
72. van den Hurk CJ, Breed WP, Nortier JW. Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. *Support Care Cancer.* 2012; 20:3255–3260. [PubMed: 22539051]
73. Lemieux J, Maunsell E, Provencher L. Prospective cohort study of chemotherapy-induced alopecia with or without scalp cooling. *J Clin Oncol.* 2012; 30(Suppl) al. e. abstr 9138.
74. Betticher DC, Delmore G, Breitenstein U, et al. Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. *Support Care Cancer.* 2013; 21:2565–2573. [PubMed: 23636645]
75. Katsimbri P, Bamias A, Pavlidis N. Prevention of chemotherapy-induced alopecia using an effective scalp cooling system. *Eur J Cancer.* 2000; 36:766–771. [PubMed: 10762750]
76. Protiere C, Evans K, Camerlo J, et al. Efficacy and tolerance of a scalp-cooling system for prevention of hair loss and the experience of breast cancer patients treated by adjuvant chemotherapy. *Support Care Cancer.* 2002; 10:529–537. [PubMed: 12324807]
77. Peck HJ, Mitchell H, Stewart AL. Evaluating the efficacy of scalp cooling using the Penguin cold cap system to reduce alopecia in patients undergoing chemotherapy for breast cancer. *Eur J Oncol Nurs.* 2000; 4:246–248. [PubMed: 12849021]
78. Witman G, Cadman E, Chen M. Misuse of scalp hypothermia. *Cancer Treat Rep.* 1981; 65:507–508. [PubMed: 7237471]
79. Forsberg SA. Scalp cooling therapy and cytotoxic treatment. *Lancet.* 2001; 357:1134. [PubMed: 11303618]
80. Christodoulou C, Tsakalos G, Galani E, Skarlos DV. Scalp metastases and scalp cooling for chemotherapy-induced alopecia prevention. *Ann Oncol.* 2006; 17:350. [PubMed: 16166175]
81. Lemieux J, Amireault C, Provencher L, Maunsell E. Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling. *Breast Cancer Res Treat.* 2009; 118:547–552. [PubMed: 19241158]
82. Anderson JE, Hunt JM, Smith IE. Prevention of doxorubicin-induced alopecia by scalp cooling in patients with advanced breast cancer. *BMJ.* 1981; 282:423–424. [PubMed: 6780057]
83. Dean JC, Griffith KS, Cetas TC, et al. Scalp hypothermia: a comparison of ice packs and the Kold Kap in the prevention of doxorubicin-induced alopecia. *J Clin Oncol.* 1983; 1:33–37. [PubMed: 6668482]
84. Minisini AM, Tosti A, Sobrero AF, et al. Taxane-induced nail changes: incidence, clinical presentation and outcome. *Ann Oncol.* 2003; 14:333–337. [PubMed: 12562663]
85. De Giorgi U, Rosti G, Monti M, Frassinetti GL, Marangolo M. Onycholysis secondary to multiple paclitaxel 1-hour infusions: possible role for its vehicle (Cremophor EL). *Ann Oncol.* 2003; 14:1588–1589. [PubMed: 14504063]
86. Nicolopoulos J, Howard A. Docetaxel-induced nail dystrophy. *Australas J Dermatol.* 2002; 43:293–296. [PubMed: 12423438]
87. Flory SM, Solimando DA Jr, Webster GF, et al. Onycholysis associated with weekly administration of paclitaxel. *Ann Pharmacother.* 1999; 33:584–586. [PubMed: 10369623]
88. Wasner G, Hilpert F, Schattschneider J, et al. Docetaxel-induced nail changes--a neurogenic mechanism: a case report. *J Neurooncol.* 2002; 58:167–174. [PubMed: 12164689]
89. Scotte F, Tourani JM, Banu E, et al. Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. *J Clin Oncol.* 2005; 23:4424–4429. [PubMed: 15994152]
90. Scotte F, Banu E, Medioni J, et al. Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. *Cancer.* 2008; 112:1625–1631. [PubMed: 18286527]
91. Hayashi T, Fujita T, Mase T, et al. Phase II clinical study of protection of nail change and skin toxicity by using a frozen glove in Japanese patients with early breast cancer treated by docetaxel and cyclophosphamide (TC) [TBCRG-03 Study]. *Cancer Res.* 2009; 69(24 Suppl) Abstract 808.
92. Sakurai M, Todaka K, Takada N, et al. Multicenter phase II study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity for the breast cancer patients (Kinki

- Multidisciplinary Breast Oncology Group: KMBOG-0605). *Cancer Res.* 2009; 69(2 Suppl) Abstract 4093.
93. Ishiguro H, Takashima S, Yoshimura K, et al. Degree of freezing does not affect efficacy of frozen gloves for prevention of docetaxel-induced nail toxicity in breast cancer patients. *Support Care Cancer.* 2012; 20:2017–2024. [PubMed: 22086405]
 94. Can G, Aydinler A, Cavdar I. Taxane-induced nail changes: predictors and efficacy of the use of frozen gloves and socks in the prevention of nail toxicity. *Eur J Oncol Nurs.* 2012; 16:270–275. [PubMed: 21784705]
 95. Begon E, Blum L, Fraboulet G, Assouad S, Bachmeyer C. Frostbite as a complication of frozen gloves in the prevention of docetaxel-induced onycholysis. *Eur J Dermatol.* 2011; 21:628–629. [PubMed: 21697040]
 96. Hazin R, Abuzetun JY, Daoud YJ, Abu-Khalaf MM. Ocular complications of cancer therapy: a primer for the ophthalmologist treating cancer patients. *Curr Opin Ophthalmol.* 2009; 20:308–317. [PubMed: 19491683]
 97. Renouf DJ, Velazquez-Martin JP, Simpson R, Siu LL, Bedard PL. Ocular toxicity of targeted therapies. *J Clin Oncol.* 2012; 30:3277–3286. [PubMed: 22649132]
 98. Loprinzi CL, Love RR, Garrity JA, Ames MM. Cyclophosphamide, methotrexate, and 5-fluorouracil (CMF)-induced ocular toxicity. *Cancer Invest.* 1990;8459–465.
 99. Eiseman AS, Flanagan JC, Brooks AB, Mitchell EP, Pemberton CH. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. *Ophthalm Plast Reconstr Surg.* 2003; 19:216–224.
 100. Imperia PS, Lazarus HM, Lass JH. Ocular complications of systemic cancer chemotherapy. *Surv Ophthalmol.* 1989; 34:209–230. [PubMed: 2694416]
 101. Christophidis N, Vajda FJ, Lucas I, Louis WJ. Ocular side effects with 5-fluorouracil. *Aust N Z J. Med.* 1979; 9:143–144. [PubMed: 287454]
 102. Doroshow JH, Locker GY, Gaasterland DE, et al. Ocular irritation from high-dose methotrexate therapy: pharmacokinetics of drug in the tear film. *Cancer.* 1981; 48:2158–2162. [PubMed: 7296473]
 103. Brink HM, Beex LV. Punctal and canalicular stenosis associated with systemic fluorouracil therapy. Report of five cases and review of the literature. *Doc Ophthalmol.* 1995; 90:1–6. [PubMed: 8549238]
 104. Loprinzi CL, Wender DB, Veeder MH, et al. Inhibition of 5-fluorouracil-induced ocular irritation by ocular ice packs. *Cancer.* 1994; 74:945–948. [PubMed: 8039123]
 105. Peterson DE, Ohrn K, Bowen J, et al. Systematic review of oral cryotherapy for management of oral mucositis caused by cancer therapy. *Support Care Cancer.* 2013; 21:327–332. [PubMed: 22993025]
 106. Keefe DM, Schubert MM, Elting LS, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. *Cancer.* 2007; 109:820–831. [PubMed: 17236223]
 107. Can G, Demir M, Erol O, Aydinler A. A comparison of men and women's experiences of chemotherapy-induced alopecia. *Eur J Oncol Nurs.* 2013; 17:255–260. [PubMed: 22901547]
 108. Hilton S, Hunt K, Emslie C, Salinas M, Ziebland S. Have men been overlooked? A comparison of young men and women's experiences of chemotherapy-induced alopecia. *Psychooncology.* 2008; 17:577–583. [PubMed: 17957733]
 109. Hudes GR, Lipsitz S, Grem J, et al. A phase II study of 5-fluorouracil, leucovorin, and interferon-alpha in the treatment of patients with metastatic or recurrent gastric carcinoma: an Eastern Cooperative Oncology Group study (E5292). *Cancer.* 1999; 85:290–294. [PubMed: 10023694]
 110. Baydar M, Dikilitas M, Sevinc A, Aydogdu I. Prevention of oral mucositis due to 5-fluorouracil treatment with oral cryotherapy. *J Natl Med Assoc.* 2005; 97:1161–1164. [PubMed: 16173332]
 111. Katranci N, Ovayolu N, Ovayolu O, Sevinc A. Evaluation of the effect of cryotherapy in preventing oral mucositis associated with chemotherapy - a randomized controlled trial. *Eur J Oncol Nurs.* 2012; 16:339–344. [PubMed: 21911313]
 112. Lemieux J. Reducing chemotherapy-induced alopecia with scalp cooling. *Clin Adv Hematol Oncol.* 2012; 10:681–682. [PubMed: 23187775]

113. van den Hurk CJ, van den Akker-van Marle ME, Breed WP, et al. Impact of scalp cooling on chemotherapy-induced alopecia, wig use and hair growth of patients with cancer. *Eur J Oncol Nurs*. Apr 6.2013 Epub ahead of print.

Table 1

Studies of Oral Cryotherapy in Solid Malignancies

Reference	Year	Randomized	No. in Intervention/Control Group	Type of Cryotherapy	Duration of Cryotherapy	Chemo Regimen	Mucositis Staging	Intervention Group	Control Group
Mahood ¹³	1991	Yes	50/45	Ice chips	5 min pre-5FU and then for 30 min	5FU/LV	Mean patient and physician judged mucositis grading (0-4), mean score	Patient: 1.1 Physician: 0.9	2.4 1.9
Rocke ³⁰	1993	Yes	89/89 ^d	Ice chips	5 min pre-5FU and then for 30 or 60 min	5FU/LV	Mean patient and physician judged mucositis grading (0-4), mean score	Patient: 30 min: 0.73 60 min: 1 Physician: 30 min: 0.58 60 min: 0.79	
Cascinu ¹⁴	1994	Yes	44/40	Ice chips	5 min pre-5FU and then for 30 min	5FU/LV +/- etoposide or interferon	Combined patient and physician judged mucositis grading (0-4), mean score	0.59	1.1
Dreitet ²⁵	1997	No	37/-	Ice chips	30 min prior to edetrexate infusion	Edetrexate	ECOG grade, Grade 3-4	38%	
Gandara ²⁶	1997	No	23/-	Ice chips	5 min pre, during, and 15 min after edetrexate infusion	Edetrexate + carboplatin	Not specified, Grade 3	13%	
Edelman ²²	1998	No	46/-	Ice chips	5 min pre, during, and 15 min after edetrexate infusion	Edetrexate + carboplatin	CTC, Grade 1-4	Grade 1-2: 59% Grade 3-4: 15%	
Hudes ¹⁰⁹	1999	No	27/-	Ice chips	5 min pre-5FU and then for 30 min	5FU/LV + Interferon	CTC, Grade 3-4	36%	
Yokomizo ²⁹	2004	No	20/32	Allopurinol ice balls	Prior to 5FU infusion and at 2, 4, and 6 hours until melted	5FU/LV	CTC, Grade 1-4	Grade 1-2: 15% Grade 3-4: 0%	41% 6%
Karagozoglu ²⁰	2005	Yes	30/30	Smooth ice cubes	5 min pre-chemo until all infusions complete	Etoposide, cisplatin, mitomycin, vinblastine	Patient and physician judged mucositis grading (0-4), Grade 1-4	Patient: 37% Physician: 10%	90% 50%
Nikolletti ³¹	2005	Yes	67/67/67 ^b	Plain ice or flavored ice	5 min pre and during, until 20 min after 5FU	5FU +/- LV	Oral Assessment Guide, ORC	None vs. Plain: 3.26 None vs. flavored: 3.5 Plain vs. flavored: 1.07	

Reference	Year	Randomized	No. in Intervention/Control Group	Type of Cryotherapy	Duration of Cryotherapy	Chemo Regimen	Mucositis Staging	Intervention Group	Control Group
Baydar ¹⁰	2005	Yes	45/54 ^d	Ice chips	Start of infusion until 10 min after 5FU	5FU/LV	WHO, Grade 1-3	7% (only Grade 1)	39% (Grade 1-3)
Papadakis ³²	2007	Yes	36/40	Crushed ice	5 min pre and during, until 30 min after 5FU	5FU/LV	Patient and physician judged mucositis grading (0-4); Grade 3	Patient: 17% Physician: 11%	23% 13%
Sorensen ²¹	2008	Yes	70/64/63 ^e	Crushed ice	10 min pre-5FU and then for 35 min	5FU/LV	CTC, Grade 3	Cryotherapy: 10% Chlorhexidine: 11%	32%
Karanci ¹¹¹	2011	Yes	30/30	Crushed ice	5 min pre, during, and up to 15 min after 5FU	5FU/LV	WHO, Grade 3	3%	20%

Kadakia et al.

5FU = 5-fluorouracil; LV = leucovorin; WHO = World Health Organization; CTC = Common Toxicity Criteria; OR = odds ratio; ECOG = Eastern Cooperative Oncology Group.

^a Patients were randomized to either 30 or 60 minutes of oral cryotherapy.

^b All 67 patients were randomized sequentially in a crossover design during three cycles of therapy to flavored ice, plain ice, and no ice.

^c Reported by authors only as OR as odds of symptoms increasing vs. not increasing.

^d 40 patients in total, patients were randomized to either cryotherapy ($n=45$) or standard care ($n=54$) initially and then crossed-over at next cycle.

^e Arms A/B/C are chlorhexidine/normal saline/cryotherapy, respectively.

Table 2

Studies of Oral Cryotherapy in Hematological Malignancies

Reference	Year	Randomized	No. in Intervention/Control Group	Type of Cryotherapy	Duration of Cryotherapy	Chemo Regimen	Mucositis Staging	Intervention Group	Control Group
Dumontet ¹⁵	1994	No	22/-	Ice chips + cold water	5 min pre melphalan and continued for 30 min	Mel or BEAM ± TBI	WHO, Grade 3-4	TBI: 86% No TBI: 33%	
Meloni ¹⁶	1996	No	18/-	Ice popsicles	5 min pre, during, and 5 after melphalan infusion	Mel or BEAM	WHO, Grade 4	6%	
Aisa ³³	2005	No	18/7 (historical control)	Ice chips + cold water	15 min pre and during, until 90 min after melphalan infusion	Mel + Flu ± Other ¹	CTC, Grade 2-3	11%	86%
Mori ³⁶	2006	No	17/18 ^b	Ice chips + cold water	15 min pre and during, until 60 or 90 min after melphalan infusion	Mel + Flu ± Other ^a	CTC, Grade 2-3	60 min: 11.8% 120 min: 11.1%	-
Lilleby ³⁵	2006	Yes	21/20	Ice chips	30 min pre and during, until 6 hours after infusion	Mel	CTC, Grade 3-4	14%	74%
Svanberg ³⁷	2007	Yes	39/39	Ice chips or ice water	During infusion of chemotherapy	Variable	Modified Oral Mucositis Assessment score ^c	Autologous=1.6 Allogeneic=3.7	4.3 11.6
Gori ³⁹	2007	Yes	62/60	Ice chips	At least 60 min once methotrexate infusion started	Methotrexate	CTC, Grade 3-4	47%	53%
Bhatt ³⁴	2010	No	12/13 (historical cohort)	Ice chips	30 min prior to until infusion complete	Mel	CTC, Grade 3	17%	38%
Svanberg ³⁸	2010	Yes	39/39	Ice chips or cold water	During infusion of chemotherapy	Variable	WHO, Grade 3-4	36%	62%

Mel = melphalan; BEAM = carmustine, etoposide, cytarabine, and melphalan; TBI = total body irradiation; Flu = fludarabine; WHO = World Health Organization; CTC = Common Toxicity Criteria.

^aOther - included total body irradiation vs. craniospinal irradiation vs. high-dose cytarabine.

^bStudy compared two different total durations of oral cryotherapy, 60 min (n=17) and 120 min (n=18).

^cBased on modified Oral Mucositis Assessment Score; Autologous group (n=62) index ranged 0-5; Allogeneic group (n=16) index ranged 0-16.

Table 3

Recent Studies of Scalp Hypothermia

Reference	Year	Randomized	No. in Intervention/ Control Group	Cooling Method	Chemo Regimen	Hair Loss Grading	Intervention Group	Control Group
Mols ⁶⁸	2009	No	98/168	Paxman system	AC, FEC, FAC, DAC	No wig required	52%	3%
Auvinen ⁶⁹	2010	No	64/-	Gel-cap	A, D, D+FEC, FEC	Modified CTC, ^a Grade 1 Grade 2	69% 17%	-
Kargat ⁷⁰	2011	No	31/32	Penguin Cap	D, ABVD, BEP, CHOP	WHO, Grade 3 or 4 Week 2 Week 6	23% 50%	61% 75%
van den Hurk ⁷¹	2012	No (registry)	1411/-	Various	Various	No wig required	50%	-
van den Hurk ⁷²	2012	No ^b	53/15	Paxman system	D	No wig required 90 min PICT 45 min PICT	79% 95%	27%
Lemieux ¹¹²	2012	No	110/26	Penguin Cap or Dignicap	Various	Success per: ^c Hairstylist Patient	34% 49%	9% 4%
Van den Hurk ¹¹³	2013	No	160/86	Paxman system	Various	WHO, Grade 2 Grade 3	50% 30%	7% 91%
Betticher ⁷⁴	2013	No	128/71/39 ^d	Paxman system or cold cap	D as weekly or Q 3 weekly ± other chemotherapy	WHO Grade 3 or 4 Paxman D Q 3 week D Q weekly Cold cap D Q 3 week D Q weekly	23% 7% 27% 8%	74% 17%

AC = adriamycin, cyclophosphamide; FEC = 5-fluorouracil, epirubicin, cyclophosphamide; FAC = 5-fluorouracil, adriamycin, cyclophosphamide; DAC = docetaxel, adriamycin, cyclophosphamide; A = adriamycin; D = docetaxel; ABVD = adriamycin, bleomycin, vinblastine, dacarbazine; BEP = bleomycin, etoposide, cisplatin; CHOP = cyclophosphamide, adriamycin and vincristine plus prednisolone; WHO = World Health Organization; CTC = Common Toxicity Criteria; Q = every/

^aModified CTC were used: Grade 0=No hair loss, Grade 1=Thinning of hair, and Grade 2= Patchy or major hair loss or complete alopecia.

^bThe study was an observational study followed by randomization if the initial phase of study suggested significant benefit.

^cSuccess was defined as moderate, little, or no hair loss.

^dStudy compared three groups: Paxman system=128, cold cap=71, and control=39.

Table 4

Studies of Regional Hypothermia for the Prevention of Onycholysis

Reference	Year	No. in Intervention/Control Group ^a	Chemo Regimen	Nail Toxicity Scale	Intervention Group ^b	Control Group
Scott ⁸⁹	2005	45	Docetaxel 75 mg/m ² ± other chemotherapy	CTC, Grade 1 or 2	27%	51%
Scott ⁹⁰	2008	50 (foot)	Docetaxel 70-100 mg/m ² ± other chemotherapy	CTC, Grade 1 or 2	0%	21% -
Sakurai ⁹²	2009	70/52 ^c	Docetaxel 75 mg/m ² ± other chemotherapy	CTC, Grade 1 or 2 Grade 2 or 3	54% 4%	74% 18%
Hayashi ⁹¹	2009	52 ^d	Docetaxel 75 mg/m ² + Cyclophosphamide	CTC, Grade 1 or 2	19%	37%
Ishiguro ⁹³	2011	23 ^e	Docetaxel 40 mg/m ² ± other chemotherapy	CTC, Grade 1 or 2 -25 to -30°C for 90 min -10 to -20°C for 60 min	0% 0%	
Can ⁹⁴	2012	55/145 ^f	Docetaxel or paclitaxel (variable dose) ± other chemotherapy	CTC, Grade 1, 2, or 3 Paclitaxel Q 7 days Paclitaxel Q 21 days Docetaxel Q 21 days	56% 50% 38%	43% 53% 50%

CTC = Common Toxicity Criteria.

^a All studies, unless indicated otherwise, used one hand as the control and the other as the intervention.

^b All studies, unless indicated otherwise, used a frozen glove at -25 to -30°C for a duration of 90 minutes; 15 minutes prior to, during, and 15 minutes after the infusion of docetaxel.

^c Both hands in intervention group were provided with frozen group; control group did not receive any intervention

^d Frozen glove was worn for 15 minutes prior to, during, and 30 minutes after the infusion of docetaxel.

^e One hand received standard frozen glove and other received frozen glove at -10 to -20°C for 60 min (see text).

^f Intervention group received frozen gloves and socks on all extremities; control group received neither.